Announced
Completed
Synopsis
Eli Lilly, a private equity firm, completed a $35m investment in Precision BioSciences, a biotechnology company. "Gene-edited therapies are emerging as a promising approach to help patients afflicted with genetic conditions. We look forward to working closely with Precision's scientific team and leveraging their platform to develop and deliver breakthrough medicines for untreated genetic disorders," Ruth Gimeno, Eli Lilly Vice President.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.